Business, energy, technology, markets and global industry news from Business News Today

maralixibat

PharmaDeviceNews maralixibat
Representative image of AI-enabled liver disease research, reflecting how insitro’s CTRO-1013 MASH candidate is being studied for anti-fibrotic signals beyond liver fat reduction.
Pharma & Biotech

LIVMARLI cuts bile acids 70% in Phase 3. Can Mirum turn its biliary atresia breakthrough into FDA approval?

Mirum's LIVMARLI meets its Phase 3 itch endpoint and cuts bile acids, supporting a planned 2027 FDA filing for rare liver diseases.

Read More
Editorial infographic highlighting Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Phase 3 EXPAND trial, featuring liver illustrations, clinical research graphics and an October 12 results announcement, with emphasis on evaluating itching relief in additional rare liver diseases.
Pharma & Biotech

Mirum’s EXPAND study tests maralixibat for treatment-resistant cholestatic pruritus

Mirum will reveal LIVMARLI EXPAND Phase 3 results on October 12, testing whether maralixibat can treat itching in additional rare liver diseases.

Read More
Representative image: Rare liver disease research is gaining fresh attention as Mirum Pharmaceuticals reports new EASL 2026 data on volixibat, brelovitug, and LIVMARLI.
Pharma & Biotech

Why clinicians and investors are watching Mirum Pharmaceuticals after its EASL 2026 update

Find out how Mirum Pharmaceuticals’ EASL 2026 data could reshape rare liver disease treatment and investor sentiment.

Read More
Representative image of a hepatology researcher reviewing rare liver disease clinical data, reflecting Mirum Pharmaceuticals’ EASL 2026 updates on volixibat, brelovitug and maralixibat across PSC, HDV and PFIC programs.
Pharma & Biotech

Can volixibat and brelovitug expand Mirum Pharmaceuticals’ rare liver disease ambitions?

Mirum Pharmaceuticals’ EASL 2026 data deepen its rare liver disease strategy. Find out what changes for PSC, HDV and PFIC care.

Read More